Dr. Arkady Mandel reports

THERALASE(R) TO HOST ADVISORY BOARD MEETINGS AT CANADIAN UROLOGICAL ASSOCIATION BLADDER CANCER FORUM AND THE AMERICAN UROLOGICAL ASSOCIATION

Theralase Technologies Inc. is hosting advisory board meetings to present the latest study 2 interim clinical data to its principal investigators (PIs) at the Canadian Urological Association (CUA) Bladder Cancer Forum and the American Urology Association (AUA), respectively.

Study 2 is a phase 2 clinical study that provides a study procedure (study drug activated by a study device) for patients diagnosed with bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in Toronto, Ont., to provide an update to all Canadian principal investigators (PIs) of the study 2 interim clinical data and to discuss opportunities for patient enrolment.

An advisory board meeting is scheduled to take place on May 4, 2024, during the 2024 American Urology Association meeting in San Antonio, Tex., to provide an update to all Canadian- and United States-based PIs of the study 2 interim clinical data and to discuss opportunities for patient enrolment.

Arkady Mandel MD, PhD, DSc, chief scientific officer of Theralase, stated: "Patients with BCG-unresponsive NMIBC CIS have limited treatment options other than bladder removal surgery. We look forward to discussing the strong, interim clinical data from study 2 with the PIs of the study, who are key opinion leaders in the Canadian and U.S. urologic community. The interim clinical data to be presented details the safety and efficacy of Ruvidar-based photodynamic therapy PDT for the treatment of BCG-unresponsive NMIBC CIS. The current interim phase 2 clinical study analysis demonstrates a significant clinical advantage of the Theralase technology in the current treatment landscape, and provides potential for a novel, effective and lasting treatment option for these patients. Moving forward, we are continuing to advance new patient recruitment with the goal of completing patient recruitment for our phase 2 study by year-end."

About Theralase Technologies Inc.

Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

We seek Safe Harbor.